Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Expansion builds on favorable efficacy and safety data from Part A of the LIGHTHOUSE study Enrollment of pivotal cohort expected to begin in Q1 2026; BLA submission anticipated in early 2028 ATSN-201 ...

Detailed price information for Mustang Bio Inc (MBIO-Q) from The Globe and Mail including charting and trades.

The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors ...

Detailed price information for Mustang Bio Inc (MBIO-Q) from The Globe and Mail including charting and trades.

Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

The US FDA has published more than 200 complete response letters sent as replies to drug and biological product applications.

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization ...

Nearly 150 new Florida laws went into effect July 1 and some of them make big changes you need to know. Here's the list.